Dr. Asim Amin, MD

Dr. Amin practices at Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health.

Dr. Amin's NPI, 1518965607, was assigned on July 12, 2005. Dr. Amin holds North Carolina license 2005-01680.

Dr. Amin's primary practice is Atrium Health Carolinas Medical Center, at 1000 Blythe Blvd, Charlotte, NC 28203 in Mecklenburg County. The practice phone is (704) 355-2000.

Dr. Amin's primary practice is Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health. Dr. Amin is also affiliated with Atrium Health Cabarrus. The medical group on file is Atrium Health Levine Children's Gastroenterology. Dmand AI also links Dr. Amin to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amin practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Amin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Amin is licensed in North Carolina.

CMS data shows 677 Medicare services from Dr. Amin across 3 procedure codes in 2024, all of them office visits, for 194 Medicare patients. Medicare paid $62,375 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 194 Medicare patients who saw Dr. Amin in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 6% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amin's median patient age at 73, with 32% women.

In 2024, Dr. Amin wrote 693 Medicare Part D claims for 106 patients. 61% of them were for generic drugs. CMS names the drug for 563 of them, across 15 drugs with 11 or more claims each, at $3,629,265 in total drug cost. In 2023, CMS named 444 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Amin for performance year 2024, reported as part of a group. Dr. Amin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amin as offering telehealth.

Dmand AI links 64 papers to Dr. Amin, published from 2010 to 2024. 2015 was the busiest year, with 8. The most frequent topics are Cell Line, Tumor, Head and Neck Neoplasms and Antineoplastic Agents. Dr. Amin has published most often in Cancer Prev Res (Phila). Dr. Amin's most frequent co-authors are Hans Joerg Hammers, MD, PhD, David Francis McDermott, MD and Fadlo R. Khuri, MD.

Dmand AI links Dr. Amin to 2 clinical trials. Conditions studied include Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck and Carcinoma, Squamous Cell. Open Payments lists research payments to Dr. Amin that name 1 trial.

CMS Open Payments shows 252 general payments to Dr. Amin from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. Bristol-Myers Squibb Company paid the most, $96,644. It also lists 9 research payments totaling $1,207 in 2025, naming 1 clinical trial.